289 related articles for article (PubMed ID: 16146534)
21. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
Arranz R; Conde E; Grande C; Mateos MV; Gandarillas M; Albo C; Lahuerta JJ; Fernández-Rañada JM; Hernández MT; Alonso N; García Vela JA; Garzón S; Rodríguez J; Caballero D;
Eur J Haematol; 2008 Mar; 80(3):227-35. PubMed ID: 18088400
[TBL] [Abstract][Full Text] [Related]
22. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Gill P; Litzow M; Buckner J; Arndt C; Moynihan T; Christianson T; Ansell S; Galanis E
Cancer; 2008 Apr; 112(8):1805-11. PubMed ID: 18300237
[TBL] [Abstract][Full Text] [Related]
23. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
24. Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient.
Ozkaynak MF
J Pediatr Hematol Oncol; 2009 Feb; 31(2):128-30. PubMed ID: 19194199
[TBL] [Abstract][Full Text] [Related]
25. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
26. [Comparison of the effectiveness of chemotherapy and autologous hematopoietic stem cell transplantation as postremission treatment for adult acute lymphoblastic leukemia patients].
Jin FY; Zou DH; Wang GR; Xu Y; Feng SZ; Zhao YZ; Han MZ; Yan WW; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2005 Nov; 26(11):645-8. PubMed ID: 16620547
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of primary central nervous system lymphoma in the immunocompetent patient].
Sierra Del Rio M; Benouaich-Amiel A; Psimaras D; Dehais C; Hoang-Xuan K
Rev Neurol (Paris); 2008; 164(6-7):569-74. PubMed ID: 18565356
[TBL] [Abstract][Full Text] [Related]
28. [Autologous hematopoietic stem cell transplantation for aggressive B-cell non-Hodgkin's lymphoma].
Hirose A; Yamane T; Nakajima Y; Manabe M; Kanashima H; Hagihara K; Sakamoto E; Nakamae M; Terada Y; Kosaka S; Aoyama Y; Sakamoto C; Kumura T; Koh KR; Hirai M; Ohta K; Nakao Y; Mugitani A; Teshima H; Hino M
Gan To Kagaku Ryoho; 2005 Dec; 32(13):2059-64. PubMed ID: 16352929
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation in first-line treatment of high-risk aggressive non-Hodgkin's lymphoma.
Vranovsky A; Ladicka M; Lakota J
Neoplasma; 2008; 55(2):107-12. PubMed ID: 18652043
[TBL] [Abstract][Full Text] [Related]
30. Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
Pöttgen C; Stuschke M; Stüben G; Schmitz A; Schwechheimer K; Wacker HH; Rauhut F; Kleuker S; Wilhelm H; Grehl S; Fehlings T
Strahlenther Onkol; 2003 Sep; 179(9):626-32. PubMed ID: 14628129
[TBL] [Abstract][Full Text] [Related]
31. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
32. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders.
Komrokji RS; Oliva JL; Zand M; Felgar R; Abboud CN
Am J Hematol; 2005 Jul; 79(3):211-5. PubMed ID: 15981226
[TBL] [Abstract][Full Text] [Related]
33. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
[TBL] [Abstract][Full Text] [Related]
34. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
35. Haematopoietic stem cell transplantation for treatment of primary CNS lymphoma: single-centre experience and literature review.
Bojic M; Berghoff AS; Troch M; Agis H; Sperr WR; Widhalm G; Wöhrer A; Kalhs P; Preusser M; Rabitsch W
Eur J Haematol; 2015 Jul; 95(1):75-82. PubMed ID: 25546348
[TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation.
Buser AS; Stern M; Bucher C; Arber C; Heim D; Halter J; Meyer-Monard S; Stussi G; Lohri A; Ghielmini M; Tichelli A; Passweg JR; Gratwohl A
Bone Marrow Transplant; 2007 Mar; 39(6):335-40. PubMed ID: 17342158
[TBL] [Abstract][Full Text] [Related]
37. [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
Cui XZ; Wang HQ; Liu XM; Zhang HL; Li W
Zhonghua Xue Ye Xue Za Zhi; 2007 Sep; 28(9):609-11. PubMed ID: 18246818
[TBL] [Abstract][Full Text] [Related]
38. Estimating late adverse events using competing risks after autologous stem-cell transplantation in aggressive non-Hodgkin lymphoma patients.
Ruiz-Soto R; Sergent G; Gisselbrecht C; Larghero J; Ertault M; Hennequin C; Manson J; de Kerviler E; Briere J; Mounier N
Cancer; 2005 Dec; 104(12):2735-42. PubMed ID: 16284986
[TBL] [Abstract][Full Text] [Related]
39. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
40. A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning.
Scordo M; Bhatt V; Hsu M; Omuro AM; Matasar MJ; DeAngelis LM; Dahi PB; Moskowitz CH; Giralt SA; Sauter CS
Biol Blood Marrow Transplant; 2017 Jan; 23(1):38-43. PubMed ID: 27713090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]